Correction to “New Potent RIPK2 Inhibitors as a Promising Therapeutic Avenue for Colitis Through the Blockade of NOD Inflammatory Pathways”

IF 6.8 1区医学 Q1 CHEMISTRY, MEDICINAL

Journal of Medicinal Chemistry Pub Date : 2024-12-04 DOI:10.1021/acs.jmedchem.4c02770

Morgane Rivoal, Amélie Barczyk, Perrine Six, Xavier Dezitter, Min-Jeong Cornu-Choi, Mathilde Body-Malapel, Madjid Djouina, Christophe Waxin, Laurent Dubuquoy, Régis Millet, Natascha Leleu-Chavain

引用次数: 0

Abstract

The author list has been updated to correct the spelling of Amélie Barczyk’s surname. Additionally, ref 28 in the original article should be updated (shown here as ref (1)) as the paper has now been published in J. Med. Chem. This article references 1 other publications. This article has not yet been cited by other publications.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Medicinal Chemistry 医学-医药化学

CiteScore

4.00

自引率

11.00%

发文量

804

审稿时长

1.9 months

期刊介绍： The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents. The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.